(posted originally on linkedin [account now deleted] on 13 Oct. 2021)
The correct name of delta-9-THC [in medicine and pharmacy]: dronabinol.
Generic names, or International Nonproprietary Names (INN) are “intended for use in pharmacopoeias, labelling, product information, advertising and other promotional material, drug regulation and scientific literature, and as a basis for product names, e.g. for generics.” (WHO, 2022).
There is an INN for delta-9-tetrahydrocannabinol: “dronabinol” (WHO, 1984a, p. 6; 1984b, p. 4). It was attributed in 1984. In 2017, the INN “cannabidiol” was attributed to (–)-cannabidiol (WHO, 2017, pp. 257-8; WHO, 2017, p. 75).
While nobody ever refers to “cannabidiol” as if it was only designating a molecules obtained by chemical synthesis, excluding those obtained from botanical parts of a plant, the INN “dronabinol” is almost systematically associated solely with the “synthetic” delta-9-tetrahydrocannabinol
Is dronabinol only referencing “synthetic THC”?
The INN dronabinol is providing three references to locate the compound named:
- 1. (6aR, 10aR)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol
In WHO ECDD review documentation on THC it refers to all stereoisomers
In WHO ECDD review documentation on isomers, it refers to all isomers
- 2. CAS registry number 1972-08-3
According to ChemIDplus, CAS registry number 1972-08-3 refers to: “A psychoactive compound extracted from the resin of Cannabis sativa (marihuana, hashish). The isomer delta-9-tetrahydrocannabinol (THC) is considered the most active form, producing characteristic mood and perceptual changes associated with this compound.”
- 3. The following image:
Nothing seems to indicate that the INN is restricted to a specific enantiomer or limited to a specific method of obtention. Indeed, there is no reason to believe –as many do– that dronabinol refers only to the “synthetic version” of delta-9-tetrahydrocannabinol. This popular belief might be related to the fact that the first delta-9-THC/dronabinol medicines to be comercialized were indeed not plant-derived.
But the truth is: there is dronabinol in the decarboxylated buds of Cannabis sativa and, persons seeking to normalize cannabis in medicine generally should consider refering to the more simple, internationally-agreed INN “dronabinol” rather than on the complex chemical formula “delta-9-tetrahydrocannabinol”
After all, isn’t it more normal to refer to the INN “baclofen” than to “β-(p-chlorophenyl)-γ-aminobutyric acid“, to “cocaine” instead of “benzoylmethylecgonine“, or to “paracetamol” instead of “N-(4-Hydroxyphenyl)acetamide“.
Why would Cannabis-derived active compounds be different?
References
- World Health Organization (1984a), “List of Proposed INNs No. 51”, WHO Chronicle 38(2), https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl51.pdf?sfvrsn=3ded55af_9&download=true
- World Health Organization (1984b), “List of Recommended INNs No. 24”, WHO Chronicle 38(6), https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/rl24.pdf?sfvrsn=99779214_6&download=true
- World Health Organization (2016), “List of Proposed INNs No. 115”, In: WHO Drug Information 30(2), https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl115.pdf?sfvrsn=706acd88_9&download=true
- World Health Organization (2017), “List of Recommended INNs No. 77”, In: WHO Drug Information 31(1), https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/rl77.pdf?sfvrsn=c1e6fc91_6&download=true
- World Health Organization (2022), International Nonproprietary Names Programme and Classification of Medical Products [online] https://www.who.int/teams/health-product-and-policy-standards/inn/